Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2154
Journal of Biotechnology & Biomaterials received 2154 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Novel drug-eluting beads (DEBs) containing tyrosine kinase inhibitors (TKIs) for cancer therapy
Annual Conference and Expo on Biomaterials
Alice Hagan, Macfarlane W, Philips G, Lloyd A W, Czuczman P and Lewis A L
University of Brighton, UK Biocompatibles UK Ltd, UK
ScientificTracks Abstracts: J Biotechnol Biomater
Abstract
DEBs are embolic agents that can be loaded with anti-cancer drugs which are subsequently released over time at the tumor site following administration into the arteries that feed liver malignancies using a technique known as transarterial chemoembolization (TACE). The most commonly loaded drugs into DEB are doxorubicin and irinotecan, both cytotoxic agents that interfere with DNA replication. However, it is also possible to load DEB with certain targeted agents such as TKIs. Due to the chemical structure and properties of these compounds, it is necessary to use different methodological approaches to incorporate them into the bead matrix. We describe the loading of DC Bead™ with vandetanib, an anti-angiogenic multitargeted TKI. The molecule may exist in several pH-dependent charge states which affect both its solubility in water and capacity to occupy drug binding sites within the beads. Maximum drug loading capacity of vandetanib into DC Bead™ and a novel radiopaque version was investigated at varying pH. Uniform distribution of the drug throughout the bead was confirmed by SEM-EDX analysis. The effect of drug loading on physicochemical properties of the beads such as size, radiopacity and compressibility was examined as well as the characteristics of in vitro drug release. In order to mimic ischemia after embolization, the effect of vandetanib on HepG2 cell viability under hypoxic conditions was investigated by MTT assay. Vandetanib showed equipotency in hypoxia and normoxia across a range of concentrations with an IC50 of approximately 6.25 μM, confirming its suitability for delivery from a DEB.Biography
Alice Hagan is a Scientist at Biocompatibles UK Ltd and currently pursuing PhD at the University of Brighton. Her research focuses on novel drug-device combinations for the treatment of liver tumors. In 2014, she was awarded an Industrial Fellowship from the Royal Commission for the Exhibition of 1851, in order to pursue her research and development of drug-eluting bead products in partnership with Biocompatibles.
Email: A.E.Hagan@brighton.ac.uk
